Duke-PKU Cancer Program, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Oncology and Immunotherapy, Beijing Cancer Hospital and Institute, Peking University School of Oncology, University Cancer Hospital, 52 Fucheng Rd, Beijing, China.
Clin Transl Oncol. 2013 Jan;15(1):46-54. doi: 10.1007/s12094-012-0891-2. Epub 2012 Jul 20.
Recent studies suggest that the relationship between cancer stem cells (CSCs) and the vascular niche may be bidirectional; the niche can support the growth and renewal of CSCs, and CSCs may contribute to the maintenance of the niche. There is little knowledge concerning the role of breast cancer stem cells in promoting tumor angiogenesis.
For human breast cancers, CSCs have been shown to be associated with a CD44+/CD24- phenotype. We investigated the potential activities of CD44+/CD24- breast cancer stem cells in promoting tumor angiogenesis.
The expression of pro-angiogenic genes was determined by quantitative real-time RT-PCR. Endothelial cell migration assays were employed to evaluate effects of conditioned media from CD44+/CD24- on human umbilical vein endothelial cells. A chorioallantoic membrane (CAM) assay was used to study the potential of CD44+/CD24- cells to promote angiogenesis.
In our study, CD44+/CD24- cells expressed elevated levels of pro-angiogenic factors compared with CD44+/CD24+ cells. CD44+/CD24- cell-conditioned media significantly increased endothelial cell migration. Breast cancer cell lines enriched with CD44+/CD24- cells were more pro-angiogenic in the CAM assay than those lacking a CD44+/CD24- subpopulation. CD44+/CD24- cells sorted from MCF-7 cell lines were more pro-angiogenic in a CAM assay than CD44+/CD24+ cells. Furthermore, the VEGF concentration was significantly higher in CD44+/CD24- cell-conditioned media than in CD44+/CD24+ cell-conditioned media. The pro-angiogenic effect of CD44+/CD24- cells on endothelial cells was abolished by bevacizumab.
Our findings demonstrate that CD44+/CD24- breast cancer stem cells have substantial pro-angiogenic potential and activity. This provides new insights to explore in the development of targeted therapies.
最近的研究表明,癌症干细胞(CSC)与血管生态位之间的关系可能是双向的;生态位可以支持 CSC 的生长和更新,而 CSC 则可能有助于维持生态位。关于乳腺癌干细胞在促进肿瘤血管生成中的作用,人们知之甚少。
对于人乳腺癌,CSC 已被证明与 CD44+/CD24-表型相关。我们研究了 CD44+/CD24-乳腺癌干细胞在促进肿瘤血管生成中的潜在活性。
通过定量实时 RT-PCR 确定促血管生成基因的表达。采用内皮细胞迁移实验评估 CD44+/CD24-条件培养基对人脐静脉内皮细胞的影响。采用鸡胚尿囊膜(CAM)实验研究 CD44+/CD24-细胞促进血管生成的潜力。
在我们的研究中,与 CD44+/CD24+细胞相比,CD44+/CD24-细胞表达更高水平的促血管生成因子。CD44+/CD24-细胞条件培养基显著增加内皮细胞迁移。富含 CD44+/CD24-细胞的乳腺癌细胞系在 CAM 实验中比缺乏 CD44+/CD24-亚群的细胞系更具促血管生成能力。从 MCF-7 细胞系中分选的 CD44+/CD24-细胞在 CAM 实验中的促血管生成能力强于 CD44+/CD24+细胞。此外,CD44+/CD24-细胞条件培养基中的 VEGF 浓度明显高于 CD44+/CD24+细胞条件培养基。bevacizumab 可消除 CD44+/CD24-细胞对内皮细胞的促血管生成作用。
我们的研究结果表明,CD44+/CD24-乳腺癌干细胞具有显著的促血管生成潜力和活性。这为探索靶向治疗的发展提供了新的思路。